EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Identifying patients at risk of supratherapeutic amisulpride exposure in routine psychiatric practice: a real-world therapeutic drug monitoring study

Keyu Yan iD, Gehang Ju iD, Aowei Li, Ruomei Gao, Na Wang, Qing Shao iD

Therapeutic Advances in Psychopharmacology · 2026-07 · 16

DOI: 10.1177/20451253261460142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 07.07.2026. Verfasst von Keyu Yan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xi'an Mental Health Center, Xi'an, Shaanxi, P.R. China. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Amisulpride is an important antipsychotic used in the treatment of schizophrenia, yet its exposure shows inter-individual variability. Although therapeutic drug monitoring (TDM) is recommended, supratherapeutic concentrations (>600 ng/mL) still occur in routine practice and may increase the risk of adverse effects. However, practical risk prediction studies of supratherapeutic amisulpride exposure based on routine clinical variables remain limited.

Objectives

To identify patients at increased risk of supratherapeutic amisulpride exposure in routine psychiatric care and to develop a clinically interpretable risk prediction approach based on routinely available clinical variables.

Design

This was a retrospective observational study using real-world TDM data from psychiatric inpatients.

Methods

Therapeutic drug monitoring data were retrospectively analyzed. Patients were split at the patient level into training (70%) and validation (30%) cohorts. To identify the optimal representation of renal function and drug elimination, predictors were organized into three candidate pools: (i) apparent clearance (CL/F) calculated from the final covariate equation of a previously published population pharmacokinetic model, (ii) estimated creatinine clearance (eCLcr), and (iii) the original clinical variables used to calculate eCLcr. Within each candidate predictor pool, predictors were screened using LASSO-penalized logistic regression and then entered into multivariable logistic regression. The most clinically practical model was selected for nomogram construction. Model performance was assessed by discrimination, calibration, and decision curve analysis.

Results

A total of 413 steady-state trough samples from 299 patients were analyzed, of which 19.6% exceeded a steady-state trough plasma concentration of 600 ng/mL. Reduced renal function and higher daily doses were consistently associated with an increased risk of supratherapeutic exposure. Among the three candidate strategies, the Key Covariate-based strategy achieved acceptable discrimination in both the training (area under the receiver operating characteristic curve (AUC) 0.738) and validation (AUC 0.720) cohorts, with good calibration. Decision curve analysis suggested potential clinical utility across a range of lower to moderate threshold probabilities.

Conclusion

A simple risk stratification approach based on eCLcr and daily dose may offer a reference for individualized risk assessment. This model may provide preliminary support for identifying patients at risk of supratherapeutic exposure in routine psychiatric practice.

Schlagwörter

Stichwörter der Autor:innen

amisulpriderisk stratificationsupratherapeutic exposuretherapeutic drug monitoring

Autor:innen und Institutionen

  • Department of Pharmacy, Xi'an Mental Health Center, Xi'an, Shaanxi, P.R. China.
  • Institute of Big Data, Central South University, Changsha, Hunan, P.R. China.
  • Hunan University of Medicine General Hospital, Changsha, Hunan, P.R. China.
  • Institute of Public Health, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
  • Biomedical Big Data Center, West China Hospital of Sichuan University, Chengdu, Sichuan, P.R. China.
  • Department of Pharmacy, Xi'an Mental Health Center, No. 666, Kanghe Road, Chang'an District, Xi'an, Shaanxi, 710100, P.R. China.

ORCID-Profile: Keyu Yan, Gehang Ju, Qing Shao

Zitieren

APA

Yan, K., Ju, G., Li, A., Gao, R., Wang, N., & Shao, Q. (2026). Identifying patients at risk of supratherapeutic amisulpride exposure in routine psychiatric practice: a real-world therapeutic drug monitoring study. Therapeutic Advances in Psychopharmacology, 16. https://doi.org/10.1177/20451253261460142

Vancouver

Yan K, Ju G, Li A, Gao R, Wang N, Shao Q. Identifying patients at risk of supratherapeutic amisulpride exposure in routine psychiatric practice: a real-world therapeutic drug monitoring study. Therapeutic Advances in Psychopharmacology. 2026;16. doi:10.1177/20451253261460142

BibTeX
@article{Yan2026,
  author = {Yan, Keyu and Ju, Gehang and Li, Aowei and Gao, Ruomei and Wang, Na and Shao, Qing},
  title = {Identifying patients at risk of supratherapeutic amisulpride exposure in routine psychiatric practice: a real-world therapeutic drug monitoring study},
  journal = {Therapeutic Advances in Psychopharmacology},
  year = {2026},
  volume = {16},
  doi = {10.1177/20451253261460142}
}
Kostenlos starten →